1. Home
  2. ICON vs ARTL Comparison

ICON vs ARTL Comparison

Compare ICON & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Icon Energy Corp.

ICON

Icon Energy Corp.

HOLD

Current Price

$0.71

Market Cap

4.7M

Sector

N/A

ML Signal

HOLD

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.94

Market Cap

3.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICON
ARTL
Founded
2023
2011
Country
Greece
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
3.4M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
ICON
ARTL
Price
$0.71
$1.94
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$4.50
$30.00
AVG Volume (30 Days)
1.8M
1.2M
Earning Date
04-02-2026
11-12-2025
Dividend Yield
1317.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,449,000.00
N/A
Revenue This Year
$94.05
N/A
Revenue Next Year
$18.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
96.44
N/A
52 Week Low
$0.69
$1.52
52 Week High
$106.60
$28.60

Technical Indicators

Market Signals
Indicator
ICON
ARTL
Relative Strength Index (RSI) 26.18 42.42
Support Level $0.72 $1.69
Resistance Level $0.83 $1.94
Average True Range (ATR) 0.08 0.20
MACD 0.02 0.11
Stochastic Oscillator 8.37 76.76

Price Performance

Historical Comparison
ICON
ARTL

About ICON Icon Energy Corp.

Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: